NYSE:ASRTDepomed Stock Price, Forecast & News

$0.99

+0.03 (+3.14 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.96

Now: $0.99▼

$1.05

50-Day Range

$0.71

MA: $0.83▼

$0.96

52-Week Range

$0.55

Now: $0.99▼

$3.63

Volume1.71 million shs

Average Volume1.70 million shs

Market Capitalization$80.28 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Depomed.

2.5 Community Rank

Outperform Votes
Depomed has received 63 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Depomed has received 65 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Depomed has received 50.78% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote “Outperform” if you believe ASRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASRT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Depomed does not currently pay a dividend.
Dividend Growth
Depomed does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Depomed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,509.00 in company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:ASRT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.assertiotx.com

PhoneN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares81,375,000

Market Cap$80.28 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive ASRT News and Ratings via Email

Sign-up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.

Depomed (NYSE:ASRT) Frequently Asked Questions

How has Depomed's stock been impacted by COVID-19 (Coronavirus)?

Depomed's stock was trading at $0.9301 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ASRT shares have increased by 6.1% and is now trading at $0.9866. View which stocks have been most impacted by Coronavirus.

When is Depomed's next earnings date?

Depomed is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Depomed.

How were Depomed's earnings last quarter?

Depomed, Inc. (NYSE:ASRT) released its earnings results on Monday, May, 11th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.18. The firm had revenue of $20.92 million for the quarter, compared to analysts' expectations of $11.30 million. View Depomed's earnings history.

Has Depomed been receiving favorable news coverage?

Press coverage about ASRT stock has been trending positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Depomed earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutDepomed.

Who are some of Depomed's key competitors?

Some companies that are related to Depomed include HEXO (HEXO), ICC Labs (ICC), Amryt Pharma (AMYT), Benchmark (BMK), Green Organic Dutchman (TGOD), WeedMD (WMD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Supreme Cannabis (FIRE), Shield Therapeutics (STX), Althea Group (AGH), Delta 9 Cannabis (NINE), Flowr (FLWR) and Acerus Pharmaceuticals (ASP). View all competitors.

What other stocks do shareholders of Depomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Opko Health (OPK), Stag Industrial (STAG), Actinium Pharmaceuticals (ATNM), Sierra Oncology (SRRA), Co-Diagnostics (CODX), Catalyst Pharmaceuticals (CPRX), Enphase Energy (ENPH) and FuelCell Energy (FCEL).

Who are Depomed's key executives?

Depomed's management team includes the following people:

Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)
Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

What is Depomed's stock symbol?

Depomed trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASRT."

How do I buy shares of Depomed?

Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Depomed's stock price today?

One share of ASRT stock can currently be purchased for approximately $0.99.

How big of a company is Depomed?

Depomed has a market capitalization of $80.28 million.

What is Depomed's official website?

The official website for Depomed is www.assertiotx.com.

This page was last updated on 6/1/2020 by MarketBeat.com Staff